Could Translate Bio Inc (NASDAQ:TBIO) Go Up After Its Newest Short Interest Report?

September 30, 2018 - By Margaret Guttierez

The stock of Translate Bio Inc (NASDAQ:TBIO) registered an increase of 1.24% in short interest. TBIO’s total short interest was 40,800 shares in September as published by FINRA. Its up 1.24% from 40,300 shares, reported previously. With 41,700 shares average volume, it will take short sellers 1 days to cover their TBIO’s short positions. The short interest to Translate Bio Inc’s float is 0.15%.

The stock increased 0.50% or $0.05 during the last trading session, reaching $10. About 102,199 shares traded or 5.31% up from the average. Translate Bio, Inc. (NASDAQ:TBIO) has 0.00% since September 30, 2017 and is . It has underperformed by 15.62% the S&P500.

Translate Bio, Inc., a messenger RNA therapeutics company, engages in developing medicines to treat diseases caused by protein or gene dysfunction. The company has market cap of $451.42 million. It is developing MRT5005 that is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 for the treatment of ornithine transcarbamylase deficiency. It currently has negative earnings. It has strategic alliances with Sanofi Pasteur.

Translate Bio, Inc. (NASDAQ:TBIO) Ratings Coverage

Among 2 analysts covering Translate Bio (NASDAQ:TBIO), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Translate Bio had 2 analyst reports since July 23, 2018 according to SRatingsIntel.

Another recent and important Translate Bio, Inc. (NASDAQ:TBIO) news was published by Nasdaq.com which published an article titled: “Translate Bio to Participate in the Leerink Partners Roundtable Series: Rare Disease & Oncology” on September 25, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: